Hannah Clarke

AKY-1189 is currently under investigation in the phase 1b NECTINIUM-2 trial.

Take a look into the top data set to be presented at this year's ASCO GU Cancers Symposium in San Francisco, California.

Data showed that measurement of ctDNA and utDNA could identify patients who are most likely to remain cancer-free following systemic therapy.

The combination of enfortumab vedotin plus pembrolizumab extended event-free and overall survival in patients with MIBC who are ineligible for cisplatin-based chemotherapy.

Across 7 randomized trials, 177Lu-PSMA-617 significantly prolonged progression-free survival vs standard therapies, with no significant difference in adverse events.

The agent was granted conditional marketing authorization based on data from the phase 2/3 QUILT-3.032 trial.

Surgeons at Cleveland Clinic completed the first commericial procedure using the Hugo robot-assisted surgery system in the US.

64Cu-SAR-bisPSMA PET/CT identified a statistically significant greater number of prostate cancer lesions per patient compared with 68Ga-PSMA-11 PET/CT.

Despite early termination of the trial, its results provide scientific rationale for further investigation into targeting alternative AR domains in mHSPC.

FDA lifts boxed warnings on 6 menopausal hormone therapies following a review of the evidence on risks and benefits.

A newly published meta-analysis found that adding metastasis-directed therapy to standard of care was associated with extended progression-free survival in oligometastatic prostate cancer, without adding significant safety risks.

The phase 2 Alliance A222001 trial demonstrated that oxybutynin led to clinically meaningful improvements in hot flash frequency and quality of life among men receiving hormone therapy for prostate cancer.

The findings offer insights into how treatment may be optimized using PSMA-PET/CT results.

The following FAQs highlight key guideline recommendations relevant to clinicians regarding the early detection of prostate cancer.

The study is designed to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of NEO-811 in clear cell renal cell carcinoma.

The sildenafil oral film is expected to be commercially available in the US in March 2026.

URO-1’s FDA-cleared SUREcore and coreCARE prostate biopsy devices have been adopted at multiple Novant Health hospitals as part of a systemwide value analysis.

The application is seeking approval of Signatera CDx as a companion diagnostic to select patients with MIBC for treatment with adjuvant atezolizumab.

A recap of the FDA submissions and regulatory decisions in urology from January 2026.

ANDROMEDA is looking to build on previous findings from the LUNAR trial in recurrent, oligometastatic prostate cancer.

Cooled laser focal therapy with the ProFocal Device showed promising cancer control in patients with localized prostate cancer.

The combination was tolerable and demonstrated promising early efficacy as a 3rd-line option for patients with mCRPC.

The report highlights key trends in cancer treatment and outcomes, including detailed analyses across 3 cancer types: prostate, esophageal, and melanoma.

AVA-291 is a differentiated formulation of testosterone designed to retain androgen activity while resisting aromatization.

The prospective registry is evaluating a personalized counseling and monitoring strategy for patients who are at an increased risk of prostate cancer due to positive family history or pathogenic genetic variants.

The results highlight the early clinical potential of the device for restoring erectile function post-prostatectomy.

The safety and efficacy of the Break Wave device was assessed in the pivotal SOUND trial.

The ARID platform is evaluating the safety and efficacy of the Voro Urologic Scaffold in minimizing stress urinary incontinence following robot-assisted radical prostatectomy.